10月1日，Abivax S.A.盘中下跌5.18%，报93.89美元/股，成交额2931.93万美元。
消息面上，公司此前公布的上半年财报显示每股亏损2.43美元，远超市场预期的亏损1.08美元，偏差幅度达125%，同比亏损扩大65.31%。尽管营收295.9万美元小幅超预期，但盈利端的大幅恶化引发市场担忧。财报发布后，Wedbush将目标价从160美元下调至118美元，Truist下调至151美元；此后Wall Street Zen进一步将评级由"持有"下调至"卖出"，多重利空持续压制股价表现。
Abivax S.A.是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其核心候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，公司计划于年底前提交新药上市申请。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.